Abstract
Magnetic resonance spectroscopy (MRS) allows the quantitative assessment of neuronal integrity in vivo based on the resonance intensity of N‐acetylaspartate (NAA). A simple approach to quantitation that is commonly used is to quantify the resonance intensity of NAA with respect to creatine (Cr). In patients with ALS, NAA/Cr density is decreased in areas of the brain that contribute significantly to the corticospinal tract. Since MRS is non‐invasive, it can be easily used to monitor the evolution of regional changes in NAA/Cr over time. The changes in NAA/Cr over a period of months are small, however, and challenge the precision of the method.